At the 61st ASH Annual Meeting & Exposition, editorial board member Pier Mannuccio Mannucci discusses new therapies for von Willebrand disease. To view Part 1, click here
Questions
1. What are the advantages of von Willebrand factor (VWF)-only products? (0:05)
2. What is the safety profile of VWF-only products? (1:15)
3. What clinical scenarios involving these new products remain to be investigated? (2:20)
Pier Mannuccio Mannucci has no conflicts of interest to declare in relation to this video.
Filmed at the 61st ASH Annual Meeting & Exposition 2019, Orlando, FL, USA.
